<--- Back to Details
First PageDocument Content
Cytokines / Myeloproliferative disease / Janus kinase 2 / Essential thrombocytosis / Polycythemia vera / Polycythemia / Haematopoiesis / Chronic myelogenous leukemia / Granulocyte colony-stimulating factor / Medicine / Biology / Hematopathology
Cytokines
Myeloproliferative disease
Janus kinase 2
Essential thrombocytosis
Polycythemia vera
Polycythemia
Haematopoiesis
Chronic myelogenous leukemia
Granulocyte colony-stimulating factor
Medicine
Biology
Hematopathology

Add to Reading List

Source URL: bloodjournal.hematologylibrary.org

Download Document from Source Website

Share Document on Facebook

Similar Documents

1  Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago

1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago

DocID: 1o8ES - View Document

Molecular Diagnosis of Myeloid Neoplasias and Solid Tumors First report of mutations detected in the gene for NF-E2 Technology Myeloproliferative Neoplasms (MPN) are a group of several distinct, but clinically related ma

Molecular Diagnosis of Myeloid Neoplasias and Solid Tumors First report of mutations detected in the gene for NF-E2 Technology Myeloproliferative Neoplasms (MPN) are a group of several distinct, but clinically related ma

DocID: 1adts - View Document

Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

DocID: 19YPO - View Document

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

DocID: 19fx5 - View Document

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre

DocID: 19eKj - View Document